Sign In
Buy PTGX
$95.41
+2.18 (+2.34%)
At Close: Jun 03, 2026
Protagonist Therapeutics to Present at Upcoming Investor Conferences
07:30am, Tuesday, 05'th Sep 2023
NEWARK, CA / ACCESSWIRE / September 5, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D.
Protagonist Therapeutics: Evaluating Rusfertide's Potential For PV
02:56am, Monday, 04'th Sep 2023
Protagonist Therapeutics focuses on peptide-based drugs, primarily rusfertide, which is undergoing a Phase 3 trial for polycythemia vera. Financially, PTGX is robust with $313.4M in assets and a cash
Protagonist Therapeutics (PTGX) Is a Great Choice for 'Trend' Investors, Here's Why
09:57am, Friday, 30'th Jun 2023
Protagonist Therapeutics (PTGX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Wall Street Analysts Predict a 25.35% Upside in Protagonist Therapeutics (PTGX): Here's What You Should Know
11:02am, Thursday, 15'th Jun 2023
The consensus price target hints at a 25.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e
5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good
10:32am, Tuesday, 13'th Jun 2023
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position PCVX, PTGX, LGND
Here's Why Momentum in Protagonist Therapeutics (PTGX) Should Keep going
10:02am, Tuesday, 13'th Jun 2023
Protagonist Therapeutics (PTGX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 38.01%
11:05am, Friday, 26'th May 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 38% in Protagonist Therapeutics (PTGX). While the effectiveness of this highly sought-after metric is questiona
Protagonist Therapeutics Sees Steady If Bumpy Progress
05:18pm, Thursday, 25'th May 2023
The stock of Protagonist Therapeutics, Inc. has more than doubled so far this year due to progress on a couple of fronts. Can the rally in the shares continue in 2023?
Protagonist Therapeutics: All Quiet Heading Into An Important H2 2023
05:33pm, Wednesday, 24'th May 2023
Protagonist continues to quietly progress its pipeline, relying mainly on the polycythemia vera story to drive its business efforts. An ongoing phase 3 study will be the critical readout, but that doe
Protagonist, A Top 1% Biotech, Briefly Breaks Out On Psoriasis Enthusiasm
11:58am, Friday, 05'th May 2023
Shares of PTGX stock briefly broke out Friday after Protagonist said it plans to soon present new test results for its psoriasis drug. The post Protagonist, A Top 1% Biotech, Briefly Breaks Out On Pso
Why Shares of Protagonist Therapeutics Rose This Week
09:51pm, Thursday, 20'th Apr 2023
Protagonist Therapeutics could become a buyout target. The company's lead therapy is coming off promising results as a cancer treatment.
Protagonist (PTGX) Up on Positive Results From FRONTIER Study
01:32pm, Wednesday, 08'th Mar 2023
Protagonist (PTGX) gains as the phase II study, conducted by Janssen, achieves its primary goal.
Protagonist Therapeutics (PTGX) Moves 10.7% Higher: Will This Strength Last?
04:31am, Wednesday, 25'th Jan 2023
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further p
Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
04:05pm, Wednesday, 21'st Dec 2022
NEWARK, Calif. , Dec. 21, 2022 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V.
Can Protagonist Therapeutics (PTGX) Climb 323% to Reach the Level Wall Street Analysts Expect?
02:55pm, Monday, 05'th Dec 2022 Zacks Investment Research
The average of price targets set by Wall Street analysts indicates a potential upside of 323.4% in Protagonist Therapeutics (PTGX). While the effectiveness of this highly sought-after metric is questi
